Drug Profile


Alternative Names: FG 7516; ZK 112119

Latest Information Update: 03 Sep 2001

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Class Anxiolytics
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Alcoholism; Anxiety disorders; Epilepsy

Most Recent Events

  • 03 Sep 2001 Discontinued-preregistration for Anxiety disorders in European Union (PO)
  • 03 Sep 2001 Discontinued-Preclinical for Epilepsy in Italy (PO)
  • 03 Sep 2001 Discontinued-Clinical for Alcoholism in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top